ENTA wants EDP-484 to be used in a cocktail controlled by ENTA, not by ABBV; this means the EDP-484 cocktail won't contain ABT-493 (which is licensed to ABBV).
EDP-239 isn't potent enough to form a 2-drug combination with EDP-484, although it could be used as a third drug if it turns out that three drugs are needed.
The textbook answer is what Luly said; A nuke is the best likely choice for a partner since it too would have a high barrier to resistance. With a nuke it may be a two compound treatment.
A NS5a or a PI would not be ideal choice since they create their own RAVs. This would be a salvage treatment for those groups who had already been exposed these compounds and had a host of NS5a and PI prevalent resultant RAVs.
News 
Market Data 
Discover 
